Home » News » News » Gilead’s Drug Trial Shows Half of Patients Successfully Lowered Blood Pressure
Gilead’s Drug Trial Shows Half of Patients Successfully Lowered Blood Pressure
Submitted on:
04.07.2009
CHI member Gilead Sciences released its Phase III trial results of its experimental drug darusentan, a new treatment for patients with treatment resistant hypertension. The drug successfully lowered the blood pressure of more than half of the patients being treated with darusentan compared to one-quarter of patients taking a placebo. This encouraged investors, who were wary of Gilead's decision to focus on creating treatments for other diseases, including cardiovascular disease, causing Gilead's shares to rise 6 percent. Darusentain will be a once-a-day pill like Gilead's blockbuster HIV drug Viread, and if approved analyst believe this drug could potentially generate sales in the range of $500 million to $1 billion.
Click here to read the full article in TheStreet.com.
Back to News Items